Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1945)	10/5/2007 2:35:37 PM
From: Jibacoa	Respond to of 3722

MDT Is under slight pressure today. bigcharts.marketwatch.com Although it is expected that the FDA will approve its coated stent next week,patients with Endeavor had higher in-stent late loss than those with Taxus. (Late loss measures how much the artery wall has narrowed around the stent, and sometimes it precedes full closure of the artery.) Endeavor also had a slightly higher rate of vessel closure than Taxus, albeit the difference was not significant. MDT has support at the 54 level & resistance at 59 bigcharts.marketwatch.com It seems better to wait for the final FDA's decision.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1945)	10/8/2007 9:21:53 AM
From: Jibacoa	Respond to of 3722

As mentioned,it seems that ISIS wants to continue the UT that started on Aug 7 from the $10 level. bigcharts.marketwatch.com Today it said that it has sufficient resources to meet funding requirements through at least 2010 & expects a smaller loss for 2007. Isis Expects Narrower 2007 Loss Monday October 8, 8:09 am ET Isis Pharmaceuticals Cuts 2007 Loss Estimate, Seeing Gains From Acquisition and Collaboration CARLSBAD, Calif. (AP) -- Isis Pharmaceuticals Inc. on Monday forecast a smaller than expected loss for the year, because of an acquisition and a collaboration payment. The company now expects a loss, excluding compensation expenses, in the mid to high $20 million range. It previously expected a loss in the mid to high $40 million range. The change incorporates the recent buyout of Symphony GenIsis and closing a deal with Ortho-McNeil, a Johnson & Johnson unit. Isis received a $5 million milestone payment as part of the Ortho-McNeil deal. Analysts polled by Thomson Financial expect a loss of $21.9 million in 2007. Isis said it has sufficient resources to meet funding requirements through at least 2010. The company also received approval to give its cholesterol drug ISIS-301012 the nonproprietary name "mipomersen sodium." Snip As was also mentioned, ISIS 301012 was found to be "safe & effective" in a study of patients with inherited high LDL. It seems that the stock will be able to get back to the $20 level.<g> bigcharts.marketwatch.com Bernard